Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
503
Total raised
£3.8B
disclosed amounts
This month
£36.9M
raised so far
The capital will support international growth and two technical projects involving multiomic age assessment and an artificial intelligence health copilot.
"For most of my life, I’ve been obsessed with understanding what makes people perform at their best. Elite athletes have long understood the value of testing, tracking and continually adapting. But that approach shouldn’t be reserved for people competing at the highest level."
Most rounds here started life as a press release.
Winfred reads them overnight, pulls out the facts, checks them against Companies House and files them. It was built by C8VA, who do the same kind of work for other businesses: turning messy, unstructured material into something you can search, count and rely on.
The funding round was led by Odyssey Ventures to accelerate commercialisation and expand US operations.
"The main obstacle holding back neurotechnology today is not a lack of ideas, but hardware. MintNeuro is addressing this gap with a platform on which the entire industry can build. We were convinced to invest by its strong technology team, working chips and first long-term commercial contract"
The financing will support manufacturing expansion and commercial launch preparation ahead of clinical trials.
"For decades, continuous monitoring has been held back by the same legacy technology. This is about to change. We’re thrilled to be partnering with Ascensia, a global powerhouse in the space, to deliver, as a first step, something radically better to millions of people with diabetes,"
The oversubscription was led by Gabriel Investment Syndicate with backing from several angel groups and regional agencies.
"We are thrilled to be supported by such a strong group of investors with varied and complementary experience. Women’s health rarely gets the investment it needs or deserves; it was refreshing to see the investors understand the gap and opportunity. Oversubscribing on our first round across just 4 weeks of pitching is a testament to the plan we have in place. We are excited to get back to business and scale GLORIAH!"
The capital will support product development and clinical deployment for the rheumatic disease platform.
"Steven was a great help from start to finish, explained the process clearly, supported through the onboarding process and managed to secure us investment with an excellent angel investor. Highly recommend this platform and Steven!"
